32 results about "Piperlongumine" patented technology

The invention provides methods for the treatment of cancer in a subject using piperlongumine and/or piperlongumine analogs.

The invention provides a method for synthesizing piperlongumine compounds, wherein the compounds are coupled by adopting acromatic carboxylic acid and amido compounds in the presence of coupling reagent. The method has the advantages of mild reaction condition and simple and convenient operation method, and is suitable for batch production of the compounds.

The present invention belongs to the field of natural medicines and discloses a compound medicine composition with anti lymphoma activity containing piperlongumine and houttugnin and use thereof. Active ingredients of the compound medicine composition comprise the piperlongumine and the houttugnin in a molar ratio of 1:1 to 1:20. Through combination of the piperlongumine and the houttugnin, the compound medicine composition has a strong synergistic treatment effect on lymphoma.

The invention belongs to the field of natural medicine, and discloses a compound medicine composition with a lung cancer resistant effect and application of the compound medicine composition. Active ingredients of the compound medicine composition consist of piperlongumine and rheum emodin in a molar ratio of (1:1) to (1:10). By combining the piperlongumine and rheum emodin, a synergic effect for treating the lung cancer is relatively good.

The invention relates to application of piperlongumine in preparation of a medicine for preventing and treating immunological rejection in corneal transplantation. Researches prove that the natural compound piperlongumine can effectively relieve immunological rejection in corneal transplantation and prolong the survival time of the corneal graft in a transplant rejection animal model, and possible mechanisms comprise inhibition of generation of immune cells and local infiltration and reduction of secretion of related inflammatory cytokines. The invention proves the effectiveness of the natural compound piperlongumine in treating the immunological rejection after the corneal transplantation, and shows that the piperlongumine has great development potential and research value when being used as a new anti-rejection medicine after the corneal transplantation.

The invention belongs to the field of natural medicines, and discloses a compound medicinal composition having a function of treating Alzheimer's disease and an application of the compound medicinal composition. An active ingredient of the compound medicinal composition consists of piperlongumine and lycopene at the mass ratio of 1: (10-500). The compound medicinal composition, on the basis of a synergistic effect between the piperlongumine and the lycopene under certain dosages, is capable of treating the Alzheimer's disease.

The invention relates to the medical technology field, and provides purposes of piperlongumine used for preparing a medicine preventing cerebral arterial thrombosis. Through pharmacological test of a mouse focal cerebral ischemia model, the facts are discovered that piperlongumine can improve behavior symptoms caused by mouse cerebral ischemia reperfusion injury obviously, the cerebral infarction size is reduced, and encephaledema degree of a mouse with cerebral ischemia is lowered. Thus piperlongumine can be used for preparing a medicine preventing cerebral arterial thrombosis.

The invention discloses a piperlongumine derivative as well as a preparation method and application thereof, and belongs to the technical field of medical chemistry. The piperlongumine derivative isshown as a formula (I): the piperlongumine derivative, as well as any mixture of these forms or a pharmaceutically acceptable salt thereof, can be used as the target Keap1 molecular probe, can position and bind the Keap1 protein in a lysis solution, and can be detected in the Western-Blot at the later stage so as to provide the new means for the research of the anti-tumor effect mechanism of the piperlongumine. According to the method, 3-hydroxy-4-nitrobenzaldehyde is used as a raw material, the synthesis process is simple, efficient and rapid, and the prepared piperlongumine derivative has relatively high yield.

The invention discloses an application of piperlongumine in inhibition of NLRP3 inflammasome activation. It is found that piperlongumine can inhibit NLRP3 inflammasome activation induced by nigericin in mouse macrophages and human mononuclear macrophages, in addition, piperlongumine not only can inhibit classical NLRP3 inflammasome activation caused by nigericin, urate crystals, aluminum and other different NLRP3 inflammasome activators, but also can inhibit activation of non-classical NLRP3 inflammasome caused by intracellular LPS, can relieve peritonitis induced by urate crystallization, and can be used for treating NLRP3 inflammasome-related inflammatory diseases such as type II diabetes atherosclerosis, gout, rheumatic arthritis, rheumatoid arthritis and the like. The invention provides an effective way for treating Parkinson's multiple sclerosis, Alzheimer's disease and the like.

Disclosed are a novel piperlongumine-based compound, an immuno regulator containing as an active ingredient the compound, or a pharmaceutically acceptable salt or solvate thereof, and a health functional food for immune regulation.

The invention relates to a hypoglycemic application of piperlongumine alkaloids. The piperlongumine alkaloids comprise retrofractamide B and guineensine, in vitro alpha-glucosidase activity determination are performed on retrofractamide B and guineensine, results show that retrofractamide B and guineensine in the piperlongumine alkaloids have relatively good inhibitory effect on alpha-glucosidaseactivity and can be used for preparing drugs for treating diabetes, and a favorable material basis is provided for development of piperlongumine alkaloid drugs for treating diabetes.

The invention discloses application of piperlongumine in a herbicide for preventing and controlling an agricultural weed. The herbicide is used for preventing and controlling the agricultural weed. The active ingredient of the herbicide is piperlongumine with a concentration of 1-10 mg/mL. The agricultural weed is one or more than one selected from the group consisting of barnyard grass, sudangrass, abutilon fiber, edible amaranth, moleplant seed, amaranthus retroflexus, echinochloa oryzoides, eleusine indica, digitaria sanguinalis and spermacoce latifolia. The piperlongumine has a remarkable inhibition effect on the agricultural weed, and a natural-source herbicidal active substance is provided for prevention and control of the agricultural weed; piperlongumine can be used for preventing and treating various important agricultural weeds such as digitaria sanguinalis, abutilon fiber, barnyard grass and amaranthus retroflexus; and the characteristics of high efficiency, low toxicity, safety and the like of piperlongumine serving as a herbicide meet the requirements of creation and development of current novel pesticides.

The dental pulp stem cell culture medium comprises a basic culture medium and the following components added in the basic culture medium: ajuga decumbens sugar, opal micro powder, sodium selenite, L-glutathione, piperlongumine, magnolol, bFGF, zinc citrate and beta-sodium glycerophosphate. According to the culture medium provided by the invention, the decumbent bugle herb sugar and the opal micro powder are added; on one hand, the decumbent bugle herb sugar contributes to uniform distribution of the opal micro powder; on the other hand, with the opal micro powder, the adherence of the dental pulp stem cells is improved, the adherence time of the cells is shortened, and the proliferation efficiency of the dental pulp stem cells is improved. Piperlongumine and magnolol are added, so that the probability that the dental pulp stem cells are polluted by infectious microbes in the culture process is reduced, cell apoptosis and slow cell growth caused by the infectious microbes are avoided, and the service time of the culture medium can be prolonged. The invention further provides a culture method of the dental pulp stem cells, the culture medium is adopted, components are safe and clear, and the proliferation efficiency of the dental pulp stem cells is effectively improved.

The invention provides application of piperlongumine in preventing and treating the plant pathogenic fungi. The test concentration of the piperlongumine serving as a bactericide for preventing and treating the plant pathogenic fungi is larger than or equal to 200 mg/L; as an antibacterial active component, the piperlongumine can be used for preventing and treating fusarium wilt, botrytis cinerea, gibberellic disease, physalospora piricola, alternaria alternata, peronophythora, northern leaf blight and corynespora fallen leaf, the inhibition rate is 80% or above, and meanwhile, the piperlongumine also has relatively strong protection and treatment effects on botrytis cinerea. Tests show that the piperlongumine has a broad-spectrum bactericidal effect on plant pathogenic fungi, and a foundation is laid for further utilizing piperaceae plant piper longum to create a novel botanical fungicide.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to NO donor type piperlongumine derivatives as well as a preparation method and application thereof. The derivative provided by the invention is specifically a compound as shown in a formula (I), an isomer or pharmaceutically acceptable salt thereof, wherein R1 is selected from morpholine, pyrazine, pyrrole, furan, pyridine, quinoline, thiophene, diethylamine and derivative structures related to the morpholine, pyrazine, pyrrole, furan, pyridine, quinoline, thiophene, diethylamine and the like. R2 is selected from H or halogen. The compound, the isomer or the pharmaceutically acceptable salt of the compound can be applied to preparation of anti-tumor drugs for treatment or prevention, and particularly has good application prospects in treatment or prevention of colon cancer and non-small cell lung cancer.

A process for producing a personal care composition comprising piperlongumine the process comprising the following steps: i) adding piperlongumine to a polyol or a polyol mixture comprising less than 5 wt% of the polyol mixture of water, to form a piperlongumine pre-mix in the form of a suspension or solution; ii) adding the resulting suspension or solution to a liquid base composition.

The invention provides application of a resveratrol group containing piperlongumine analogue in medicine. The structure of the resveratrol-group piperlongumine analogue is as shown in figure (I), and the analogue is obtained on the basis of a great amount of activity screening; the analogue is good in antineoplastic activity; therefore, a new choice is provided for the development and the application of antineoplastic drugs.

The invention provides application of piperlongumine compounds in preparation of drugs for treating schistosomiasis japonicas and a pharmaceutical composition, and belongs to the technical field of drug treatment. Different substituent groups are introduced to the alpha position of Michael double bonds of piperlongumine, the obtained piperlongumine compound has efficient treatment activity on schistosoma japonicum, and the IC50 value of 72-hour in-vitro anti-schistosoma japonicum activity of the piperlongumine compound is 1-5 times that of piperlongumine. Wherein the IC50 value of the 72-hour in-vitro anti-schistosoma japonicum katsurada activity of the compound 9 is equivalent to that of clinical medicine positive control praziquantel.

The invention relates to the technical field of pharmacology, and particularly relates to a pharmaceutical composition and application thereof in delaying senescence. The pharmaceutical composition comprises felinone and piperlongumine, wherein the molar ratio of felinone to piperlongumine is (0.5-2): (1-4). The pharmaceutical composition capable of effectively delaying senescence is found, that is, after felinone and piperlongumine are compounded, drosophila melanogaster is treated, senescence of drosophila melanogaster can be effectively delayed, and the maximum life of drosophila melanogaster is prolonged. The pharmaceutical composition has great significance in the fields of delaying senescence and prolonging the overall life.

The invention discloses a cell freezing medium as well as a preparation method and application thereof. Comprising the following components: an IMDM basal culture medium, DMSO, 4-hydroxyethyl piperazine ethanesulfonic acid, pyridoxal hydrochloride, inositol, putrescine, serotonin, mercaptoethanol, arachidonic acid, cholesterol, catechin, bile alkali chloride, calcium pantothenate, nicotinamide, trehalose, polyoxypropylene polyoxyethylene, Tween 80, albumin, transferrin, fibronectin, fisetin, piperlongumine, tocopheryl acetate and linoleic acid. Linolenic acid, myristic acid, oleic acid, palmitic acid, palmitoleic acid and stearic acid; the composition further comprises amino acids, hormones, inhibitors, cell factors, inorganic compounds and vitamins. The cell cryopreservation liquid provided by the invention is used for cryopreserving mesenchymal stem cells, so that the human umbilical cord mesenchymal stem cells have high survival rate after cryopreservation and resuscitation, and meanwhile, a better differentiation capability is kept; and the cell survival rate and proliferation activity can be better maintained.